نتایج جستجو برای: ctdna
تعداد نتایج: 831 فیلتر نتایج به سال:
Recent technological advances have enabled the detection and detailed characterization of circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) in blood samples from patients with cancer. Often referred to as a "liquid biopsy," CTCs and ctDNA are expected to provide real-time monitoring of tumor evolution and therapeutic efficacy, with the potential for improved cancer diagnosis and t...
The detection of circulating tumor DNA (ctDNA) has been studied over 30 years as a method to monitor response to antiproliferative therapies in oncologic patients and, recently, to identify somatic genomic alterations. However the investigated techniques have shown limits of sensitivity, high costs, the necessity for a patientspecific optimization and a narrow-spectrum applicability. The newest...
Response assessment in lymphoma relies on imaging scans that do not capture biologic processes at the molecular level. Monitoring circulating tumor DNA (ctDNA) with next-generation sequencing-based assays can detect recurrent disease prior to scans and "liquid biopsies" for somatic mutations address tumor heterogeneity, clonal evolution, and mechanisms of resistance to guide precision treatment...
Genomic studies have provided key insights into how cancers develop, evolve, metastasize, recurrence and respond to treatment. The advance of liquid biopsy using circulating tumor DNA (ctDNA), the next-generation sequencing (NGS) and bioinformatics has led to an unprecedented view of the cancer genome and its evolution, and made the dynamic monitoring of recurrence and selective evolution of ca...
The interaction of native calf thymus DNA (CTDNA) with azorubine in 10 mM Tris–HCl aqueous solution at neutral pH 7.4 was monitored by UV-vis absorption and voltammetric techniques. Upon addition of the azorubine, UV absorption band of DNA decreased. After addition different concentrations of CT-DNA, UV absorption band of azorubine showed hyperchromisity. The binding constants (Kb) for the azor...
Advances in deep sequencing technology have led to developments in personalized medicine. Here, we describe the implications of a recent investigation that sequenced ctDNA from the plasma of non-small cell lung cancer patients to develop personalized ctDNA tests. These 'liquid biopsies' have shown promise in monitoring tumor growth and response to treatment, providing a timely overview of mutat...
Introduction Circulating tumor DNA (ctDNA) is a promising new biomarker with multiple potential applications in cancer care. As part of the “ctDNA on way to implementation Netherlands (COIN)” project, an early, comprehensive Health Technology Assessment (HTA) ongoing. Information about costs ctDNA testing essential for implementation. Estimating total cost associated ctDNA-testing challenging d...
Purpose: Targeted agents and immunotherapies promise to transform the treatment of metastatic bladder cancer, but therapy selection will depend on practical tumor molecular stratification. Circulating tumor DNA (ctDNA) is established in several solid malignancies as a minimally invasive tool to profile the tumor genome in real-time, but is critically underexplored in bladder cancer.Experimental...
A sensitive and convenient method for detecting epidermal growth factor receptor (EGFR) T790M mutations from circulating tumor DNA (ctDNA) in advanced non-small cell lung cancer (NSCLC) patients with acquired EGFR-TKI resistance would be desirable to direct patient sequential treatment strategy. A comparison of two platforms for detecting EGFR mutations in plasma ctDNA was undertaken. Plasma sa...
INTRODUCTION KRAS and EGFR ectodomain-acquired mutations in patients with metastatic colorectal cancer (mCRC) have been correlated with acquired resistance to anti-EGFR monoclonal antibodies (mAbs). We investigated the frequency, co-occurrence, and distribution of acquired KRAS and EGFR mutations in patients with mCRC refractory to anti-EGFR mAbs using circulating tumor DNA (ctDNA). PATIENTS ...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید